A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Trial Profile

A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Tralokinumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 03 Mar 2017 According to LEO Pharma media release, results will be presented at the American Academy of Dermatology (AAD) meeting 2017.
    • 03 Mar 2017 Results published in the LEO Pharma Media Release.
    • 01 Jul 2016 Top-line results published in a Leo Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top